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Abstract
Background—NIMH Project Accept (HPTN 043) was a cluster-randomized trial that tested
whether a multicomponent, multi-level prevention strategy (community-based voluntary
counselling and testing [CBVCT]) reduced HIV incidence compared to standard voluntary
counselling and testing (SVCT).
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Methods—Forty-eight communities were enrolled at five sites in South Africa, Tanzania,
Zimbabwe, and Thailand. CBVCT was designed to make testing more accessible in communities,
engage communities through outreach, and provide post-test support services. SVCT comprised
standard VCT services established at existing facilities. Communities were randomized in
matched pairs to 36 months of CBVCT or SVCT. Data were collected at baseline (n=14,567) and
post-intervention (n=56,683) by cross-sectional random surveys of 18–32 year-old community
residents. HIV incidence was estimated using a cross-sectional multi-assay algorithm. Thailand
was excluded from incidence analyses due to low HIV prevalence.
Findings—The estimated incidence in the CBVCT was 1.52% vs. 1.81% in the SVCT with an
estimated reduction in HIV incidence of 13·9% (relative risk [RR]=0·86; 95% confidence interval
[CI]=0·725–1·023; p=0·08). Women older than 24 years had RR=0·70 (95% CI=0·54–0·90;
p=0·009). CBVCT increased testing rates by 25% overall (95% CI=12%–39%; p=0·0003), by 45%
among men and 15% among women. No overall effect on sexual risk behaviour was observed.
However, among HIV-infected participants, CBVCT reduced the number of sexual partners by
8% (95% CI=1%–15%; p=0.03) and the proportion of multiple partnerships by 30% (95%
CI=8%-46%; p=0.01). Social norms regarding HIV testing were improved in CBVCT
communities.
Interpretations—The intervention was effective in increasing HIV testing, particularly among
men, promoted positive social norms regarding testing, and reduced behavioural risk among HIV-
infected participants. A modest reduction in HIV incidence was observed. This intervention
focused primarily on HIV detection. Current and future studies that include strategies for HIV
treatment and viral suppression should demonstrate further incidence reductions.
Keywords
HIV; incidence; Project Accept; Africa; HPTN 043
INTRODUCTION
Several interventions have demonstrated reduced HIV incidence in clinical trials, including
early treatment of HIV infection,1,2 use of antiretroviral therapy (ART) to prevent mother-
to-child transmission,3,4 chemoprophylaxis,5,6 and male circumcision.7–9 The challenge is to
demonstrate community-level impact on the epidemic when efficacious interventions are
taken to scale.10
NIMH Project Accept (HPTN 043) was the first cluster-randomized trial to test whether a
theory-based, multi-component, multi-level social and behavioural prevention strategy could
reduce HIV incidence within entire communities. The study hypothesis was that
community-based voluntary counselling and testing (CBVCT), relative to standard
voluntary counselling and testing (SVCT), would improve community norms about HIV
testing, reduce HIV risk behaviours, reduce HIV stigma, promptly link HIV-infected
individuals to available services, and lower HIV incidence. A major goal of the intervention
was to reduce logistical barriers to HIV testing. The intervention was designed to adapt
dynamically to changes occurring in the communities, using real-time performance
feedback.
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We have previously reported the baseline characteristics of the study population11 and the
process measures describing the intervention components and their uptake.12 At three trial
sites, the number of HIV tests performed by the VCT venues and the number of newly-
detected HIV infections were higher in CBVCT communities.
In this paper, we report the analysis of HIV incidence, the primary outcome of Project
Accept, and the analysis of secondary social and behavioural outcomes: sexual risk
behaviour, HIV testing rates, social norms regarding testing, discussions about HIV,
disclosure of HIV status, stigma associated with HIV, and HIV-related negative life events.
All outcomes were evaluated at the community level, irrespective of participation in the
intervention.
METHODS
Trial Design
Project Accept was a cluster-randomized trial conducted in 34 communities at four sites in
Africa (Soweto and KwaZulu-Natal, South Africa; Tanzania; Zimbabwe) and in 14
communities in Thailand. Baseline demographic, behavioural, and social data were collected
on a random sample of community residents between 18 and 32 years of age,11 followed by
community randomization and a 36-month intervention period13. The impact of the study
intervention was assessed across entire communities in a single cross-sectional survey
conducted at the end of the intervention period. Demographic and behavioural data and
blood samples were collected from randomly-selected individuals 18 to 32 years of age.
HIV incidence was estimated from cross-sectional data using a multi-assay algorithm
(MAA).14 The study protocol, operation manuals, and standard operating procedures are
publicly available.15 The timeline for the study is shown in Figure 1.
Definition of Clusters and Randomization
The communities (clusters) were coherent geographical areas with well-defined
boundaries.11 At the African sites, the communities were geographically close, but in most
cases were not immediately adjacent to each other. The population size of communities
varied from 5,000 to 15,000 at four sites; at the Soweto site, the typical population size was
between 15,000 and 25,000. The communities were matched into pairs prior to
randomization, based on socio-demographic, cultural, and infrastructure characteristics
determined from formative research.17 Within each pair, one community was randomly
assigned to receive CBVCT, the other received SVCT alone. Randomization was performed
centrally by the Statistical Center18. Due to the nature of the intervention, the assignment
was not blinded, except at the laboratories that analysed study samples.
Interventions
The CBVCT intervention was designed to change the context in which individuals and
communities respond to HIV.13 The four main components of the CBVCT intervention are
shown in Figure 2. The Community Mobilization component used outreach coordinators and
early testers as outreach workers to modify norms for HIV testing, encourage discussion
about HIV testing and disclosure of HIV status, increase the uptake of testing, and reduce
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stigma. The Easy Access to VCT component was designed to increase awareness of HIV
status through easily accessible VCT services provided in mobile units. The Post-Test
Support Services component provided peer-based social support groups for those who had
been tested, regardless of test results. Topics included social benefits and harms, status
disclosure, access to HIV-related services, advances in HIV treatment, and the risk of
transmitting HIV. The Real-Time Performance Feedback component ensured that pre-set
intervention goals were met.13 The SVCT intervention was comprised of VCT services
established at existing district hospitals or local health care facilities. Such services were
also available in CBVCT communities.
Participation in all intervention activities and services was open to all individuals 16 years
and older. The intervention and its adaptation to various specific settings have been
described elsewhere.13,19–21
Baseline and Post-Intervention Assessments
Data were collected in random samples of community residents, regardless of their
participation in intervention activities. The baseline assessment was conducted before
randomization and did not include HIV testing.11 The post-intervention assessment (PIA)
was conducted at the end of the intervention period, and was independent of the baseline
assessment. Eligibility criteria for participation in the baseline assessment and PIA were: age
18–32 years, current residency in the community, and ability to provide informed consent.
Households were selected with equal probability from a complete listing of community
households. At baseline, one eligible subject was randomly selected from each household to
provide detailed demographic and behavioural data. At the PIA, all eligible individuals from
the selected households were invited to participate in a brief survey and collection of blood
samples. In a subset of the households, one eligible subject was randomly selected to
complete a detailed demographic and behavioural questionnaire.
Evaluation of HIV Incidence
HIV incidence was assessed by analysing cross-sectional samples collected during the PIA.
Samples were tested in-country using HIV rapid tests; details of testing of samples are
reported in Laeyendecker, et al.14 The final HIV status of study samples was determined at
the HPTN Network Laboratory at Johns Hopkins University, as described. 14 HIV incidence
was assessed using a MAA that included the BED capture immunoassay (BED-CEIA), an
antibody avidity assay, CD4 cell count (obtained at study sites), and HIV viral load
(obtained at the HPTN Network Laboratory for a subset of samples).14 The MAA was
developed and validated using data obtained for 4,166 samples from 2,882 individuals with
known duration of infection (from 1 month to >10 years) from seven African cohorts.22 The
MAA was optimized to detect a difference in HIV incidence in southern African
populations. An antiretroviral drug (ARV) screening assay was used to exclude individuals
on ART from the incidence assessment.14
Behavioural Outcomes
Behavioural outcome measures were assessed using interviewer-administered
questionnaires. HIV testing uptake was assessed as the proportion of participants who
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reported at least one HIV test over the past 12 months. In the PIA, testing in the prior 36
months was also assessed. The social norms score was calculated as the mean of scores
(ranging from zero to three on a Likert scale) of participant’s responses to six statements
assessing their opinion on prevailing community attitudes towards HIV testing (a higher
value is associated with more positive attitudes). HIV behaviour risk score was assessed by
self-reports of monthly number of unprotected sexual acts averaged over the past six
months. Number of sexual partners was also examined in sub-analyses. Subjects who were
not sexually active in the past six months were assigned a score of zero. Negative life events
were assessed as the proportion of participants who reported any events related to
partnership break-up, discrimination, estrangement, neglect, or violence. Discussions about
HIV were measured by the proportion of participants who reported any HIV-related
conversation in the past six months. Disclosure of HIV status was measured as the
proportion of tested participants who disclosed their HIV test results to another person. HIV
stigma score was calculated as the mean of scores (on a zero to four point Likert scale)
assigned to validated 28 stigma-related scale items.23,24 A higher score was associated with
more stigma.
Sample Size
The sample size (seven pairs in Thailand with 500 assessment participants per community;
five pairs in Tanzania with 900 assessment participants per community; four pairs at the
other sites with 1,430 assessment participants per community) was calculated by an
adaptation of methods suggested by Hayes and Bennet25 to provide 80% power to detect a
35% reduction in HIV incidence. The assumptions behind the sample size calculation were:
30% prevalence, 3% annual incidence, follow-up duration 6 months, no misclassification of
incident infections, and coefficient of variation 0·26. The power was recalculated after HIV
prevalence in the communities was determined and the testing algorithm used for the HIV
incidence assessment was developed and validated. Using a weighted t-test, the study
provided over 90% power to detect a 35% reduction in HIV incidence.
Protocol Adaptations
During the study, several unexpected events warranted changes in the protocol. First, one
community pair in Soweto was removed from the study soon after the start of the
intervention due to threats of political violence. This community pair was replaced by
another; a separate randomization was performed for the new pair and all study activities
were conducted as prescribed. Data from the withdrawn community pair were not included
in any analyses. Second, the original study plan was to determine the primary HIV incidence
outcome using the BED-CEIA alone. The laboratory plan was revised because of serious
concerns about the validity of this approach.26 Third, the HIV prevalence in the 14 Thai
communities was very low (≈1%). Therefore, the incidence assessment was restricted to the
34 African communities. Fourth, quality assurance testing revealed that some stored samples
from the Soweto site were cross-contaminated.14 The contaminated samples could not be
assessed at the HPTN Network Laboratory. Finally, the standard paired t-test planned for the
primary analysis was replaced by a weighted paired t-test.
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Statistical Analysis
HIV incidence was estimated in each community using a MAA followed by an ARV
screening assay; infections classified as acute or early were included in the incidence
estimate.14 The intervention effect for each community pair was calculated as a log
incidence ratio for the CBVCT vs. the SVCT community. The overall intervention effect
was estimated by the weighted mean of pair-specific effects; the weights were proportional
to the harmonic mean of the number of incident infections observed in the paired
communities. The weighted paired t-test was used to test the hypothesis of no intervention
effect at the two-sided level of 5%. CIs were based on the weighted paired t-statistic. The
number of degrees of freedom of the reference t distribution was adjusted to take into
account unequal weights (the primary analysis used 9·4 degrees of freedom in 17 pairs). The
approximate degrees of freedom were calculated as the inverse of the sum of squared
weights minus 1. If the weights are all equal, this yields a d.f. of 16 for the classical t-test.
The test is asymptotic. We verified via simulations that the t distribution with approximated
d.f. provides better results in small samples (correct level, correct C.I. coverage) than the t-
distribution used with the classical t-test or the limiting standard normal distribution.
Subgroup analyses by age and gender were performed by the same methods on a subset of
the data; these analyses were pre-specified in the protocol.
For each behavioural outcome, community-specific means were calculated at baseline (if
available) and in the PIA. For the outcomes that were measured on one randomly-selected
household member, the means were weighted by inverse sampling probabilities to adjust for
higher chance of inclusion of participants living in smaller households. Tests of intervention
effects were performed by unweighted paired t-tests on logs of ratios of PIA community
means to baseline community means. This approach adjusts the intervention effect for
baseline differences between the communities. When the baseline mean was not available
(36-month testing rates) or baseline data were too sparse (12-month testing rates), the test
was done on log PIA means only (unadjusted for baseline). Estimates of overall and site-
specific means and intervention effects were obtained by exponentiation of averages of
community-specific means and intervention effects calculated on the log scale. Two-sided
confidence intervals (CI) are based on the t-distribution on the log scale. Subgroup analyses
were conducted by gender, and for selected outcomes also by HIV status determined by in-
country HIV rapid testing.
Implementation
Study implementation was supervised and managed by Principal Investigators and Project
Managers at the study sites. An 11-member Steering Committee (Coates[Chair], Celentano,
Chariyalertsak, Chingono, Donnell, Gray, Kulich, Mbwambo, Morin, Richter, and Sweat)
met monthly by conference call and semi-annually in person to design and approve all study
procedures, monitor study progress, and approve all modifications and study publications.
The NIMH constituted a Data and Safety Monitoring Board and Study Monitoring
Committee (DSMB/SMC) that convened semi-annually to ensure that all study objectives
were being met and that the safety of study participants was not compromised. Real-time
performance feedback was provided monthly to each study team to ensure that study
objectives were being met.
Coates et al. Page 7
Lancet Glob Health. Author manuscript; available in PMC 2014 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ethical Considerations and Consent Procedures
The trial was conducted in close partnership with established community advisory boards
and local government departments. Consent was obtained at the community level for trial
participation and randomization. Participation in all intervention activities was voluntary.
Participation in the post-intervention assessment required permission from the head of
household for approaching household members. Consent was obtained from each participant
for each component of data collection and for collection and testing of blood samples.
Ethical Review and the Role of the Funding Source
The study was approved by ethical committees for each site and by all participating
academic institutions. NIMH funding for the project was through a cooperative agreement
mechanism, allowing the NIMH Project Officer assigned to the study to participate in
technical project activities. The NIMH project officer participated in Steering Committee
meetings and reviewed DSMB/SMC reports before submission. None of the funding
agencies had any role in the study design, data collection, analysis, and interpretation, or
decision to submit for publication.
FINDINGS
Study Population
Fifty communities were enrolled, matched into pairs, and randomized; 48 of the
communities received the assigned intervention and post-intervention assessment. Because
of low HIV prevalence in the Thai site, only 34 African communities were included in the
primary endpoint analysis (Figure 3). All 48 communities participated in secondary outcome
analyses.
Community populations were well balanced between study arms (Table 1). During the
intervention, the study teams organized 15,603 community mobilization activities, provided
71,842 VCT sessions, and 51,787 post-test support service sessions. Figure 4 describes the
participant flow through the baseline assessment and PIA.A total of 84,947 potential
housing structures were visited during the PIA. Among them, 9,535 (11.2%) were non-
residential (e.g., business, storage, animal structures).Additional 34,828 (41.0%) households
were found to include no eligible participants. Response rates for primary outcome
assessment are summarized in Table 2. In African sites, nearly 60,000 potentially eligible
participants lived in selected households. Of them, 7·9% could not be contacted, 3·7%
refused participation, and 5·6% were ineligible. Among eligible participants, the response
rate for blood sample collection was 94·1%. When failure to contact participants was taken
into account, the overall response rate was 81·5%. There was no significant difference in the
response rate by study arm. The PIA included a sizeable fraction of the whole community
population: 29% of all eligible subjects in Soweto and 57–77% of all eligible subjects in the
other three African sites. Study samples were analysed at the HPTN Network Laboratory to
determine the final HIV status of study participants and to estimate HIV incidence.14 The
results of the laboratory analyses are summarized in Table 3. A total of 46,693 blood
samples were collected; 320 (0·7%) of those samples were excluded from incidence
assessment (Table 3). The HIV incidence analysis included data from 39,012 HIV-
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uninfected participants and 7,361 HIV-infected participants enrolled at the African sites. A
total of 445 samples were classified as potentially incident infections14 and formed the basis
of the HIV incidence analysis (205 in the CBVCT arm and 240 in the SVCT arm); these
samples included acute and early infections and MAA positive samples that did not have
ARV drugs detected.
Table 4 presents the demographic and behavioural characteristics of the 46,378 study
participants with known final HIV status. A total of 54·3% of these participants were
women; a slight majority of men and women were 18–24 years old. The South African sites
had on average more years of education and lower marriage levels than the other sites.
Primary Outcome
The overall HIV prevalence in the African sites was 16·5%. The highest HIV prevalence
was observed in KwaZulu-Natal (Table 6): 30·8% for all subjects, over 50% of subjects in
the age range 25–32 years; over 60% of women 25–32 years old were HIV infected. The
other sites had lower HIV prevalence: Soweto 14·1%, Zimbabwe 12·9%, and Tanzania
5·9%. At all sites, HIV prevalence in women was more than twice as high as in men, and
HIV prevalence in the older age group (25–32 years) was about three times higher than in
the younger age group (18–24 years).
We observed an overall 13.9% reduction in HIV incidence in the CBVCT intervention
communities compared to the SVCT control communities (Table 5). The 95% CI for the
relative risk (RR) was 0·73–1·02, p=0·082. The reduction in incidence was 12% among
women and 19% among men, neither of which attained significance. Little change in
incidence was observed in the younger age group (RR=0·98); the older age group had a 25%
reduction (95% CI for RR 0·54–1·04; p=0·078). The intervention effect was significant
among women in the older age group (RR=0·70; 95% CI 0·54–0·90; p=0·009).
We repeated the analysis using a more stringent MAA, as well as using a standard paired t-
test rather than weighted t-test. In both cases, we obtained very similar intervention effects,
but with larger standard errors and wider confidence intervals (data not shown).
Site-specific HIV incidence and prevalence results are presented in Table 6. Overall, the
intervention appeared to reduce incidence at all sites except Tanzania. The reduction was
quite small in KwaZulu-Natal, the site with the highest HIV incidence. In KwaZulu-Natal,
the intervention did not appear to reduce HIV incidence in the younger subgroup or among
all women, but in the older subgroup of women incidence was reduced by more than 40%.
Secondary Outcomes
The intervention increased HIV testing uptake significantly, and was especially effective in
increasing testing among men. Overall 12-month testing rates (Table 7) were 25% higher in
the CBVCT arm than in the SVCT arm (95% CI 12%-39%, p=0·0003). The largest effect on
testing uptake was observed in Thailand (56%, see Table S1 in the Online Supplement).
Testing rates over 36 months were 27% higher in the CBVCT arm (95% CI 15%-41%,
p<0·0001). Overall, 49% of the entire 18–32 years old population living in CBVCT
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communities was tested over the duration of the study, compared to 39% in SVCT
communities.
Annual testing rates in men reached 16% after the intervention period in the SVCT arm, and
24% in the CBVCT arm (Table 7), showing a 45% increase over SVCT arm (95% CI 25%–
69%, p<0·0001). At baseline, 12-month testing rates in women (around 20%) were more
than twice as large as in men (<10%), probably due to antenatal testing. After the
interventions were concluded, testing rates among women increased to 34% (SVCT) and
39% (CBVCT), which corresponds to a 15% intervention effect on testing (p=0·0134).
Among the individual sites, only Thailand had a meaningful effect on testing in women.
Soweto, South Africa was the only site that did not show a clear effect on testing rates in
men (Table S2 in the Online Supplement).
The intervention had a significant effect on community social norms regarding HIV testing
(Table 7 and Table S3 in the Online Supplement). The mean social norms score was 6%
higher in the CBVCT communities than in the SVCT communities after adjusting for
baseline differences (95% CI 3%-9%, p=0·0001). The positive change in social norms was
greater in men (8% increase) than in women (4% increase), but the intervention effect was
significant in both subgroups.
There was no intervention effect on sexual risk behaviour measured by the number of
unprotected sexual acts (Table 7 and Table S4 in the Online Supplement). However, among
HIV-infected individuals, a significant reduction of high-risk sexual behaviour was observed
in the CBVCT arm. The number of sexual partners of HIV-infected participants was reduced
by 8% (95% CI 1–15%, p=0·034) and HIV-infected men reduced the number of partners by
18% (95% CI 5%-28%, p=0·009). Additionally, the proportion of HIV-infected participants
reporting multiple partners in the six months prior to interview was 30% lower in the
CBVCT communities compared to the SVCT communities (95% CI 8%-46%, p=0·014).
This effect was stronger among HIV-infected men: 36% reported multiple partners in the
SVCT communities compared to 26% in the CBVCT communities (reduction by 29%, 95%
CI 11%-43%, p=0·006). Among HIV-infected women, self-reported multiple partnerships
were rare.
The intervention did not affect the proportion of participants who reported having
experienced negative life events or having a conversation about HIV in the past six months
(Table 7). About 80%–90% of participants who were tested for HIV reported disclosing
their status to at least one person and the proportion did not vary by intervention arm. HIV-
related stigma also was not affected by the intervention. Baseline mean stigma scores were
low (1·37 and 1·39 in the comparison and intervention arm, respectively), with slight
declines at PIA (1·21 and 1·22, respectively).
DISCUSSION
Project Accept demonstrated that a multi-component, multi-level social and behavioural
intervention can produce modest reductions in HIV incidence, especially among older
women. The intervention did not appear to reduce HIV incidence in younger people; the
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reduction in incidence among the older subgroup (25–32 years, both genders) was more
pronounced, but did not reach statistical significance. The 30% reduction in HIV incidence
among older women was consistent in nearly all community pairs and was highly
significant. The intervention improved HIV testing rates in the peak age range for HIV
infection (18 to 32 years), especially among men; increased the number of people who knew
their HIV status; and reduced HIV risk behaviours among people with HIV who might
otherwise transmit the virus to others. The effectiveness of the intervention was tested
among all community residents within the selected age range, rather than only among those
subjects who directly participated in intervention activities.
It is not clear why the intervention failed to reduce HIV incidence among younger
individuals and why most of the effect was concentrated among older women. We can only
speculate as to the reason for lack of statistically significant reduction in HIV incidence, and
these might include exclusion of Thailand from the analysis, insufficient penetration of the
intervention in key HIV-1 transmission groups and/or the need to provide more services
(e.g., active referral to and maintenance in treatment) than was provided in this community
intervention. The most important behavioural change occurred among HIV-infected men,
who reduced the number of sexual partners and occurrence of multiple partnerships. This
change could perhaps protect the primary partners of these men, most likely women older
than 25 years. However, a more in-depth analysis is needed to verify this hypothesis. During
the course of the trial, ART became widely available at most sites. The increased testing
rates in CBVCT communities should have improved treatment coverage and led to a
reduction in incidence. However, there may not have been sufficient time to see community-
wide reduction in incidence resulting from increased ART uptake. A laboratory assessment
is planned to assess ART uptake and to evaluate the possible role of ART in the intervention
effect.
This is the first documentation that we could find of programs effective in reaching men,
and increasing their HIV testing and reducing their risk behaviour to a greater degree than
among women. We believe that the increased testing among men, relative to women, was
due to more than the higher baseline among women because of more frequent use of the
healthcare system and thus more routine testing. There is a growing literature that men in
sub-Saharan Africa are less likely to access testing, and more likely to present for treatment
later in their illness and to die sooner from HIV. We believe that a Project Accept model,
that takes testing to the individual rather than having the person come to testing, might be
important for testing hard-to-reach populations such as men. Reaching men in this way
might have been important in the reductions in risk behaviour we observed among HIV+
men in the CBVCT communities.
In Project Accept we demonstrated community-wide effects from an intervention focused on
mobilization, testing, and support. The behavioural results were clearly more significant
than the declines in HIV incidence. Inclusion of accessible VCT is likely to be a key
component of an integrated combination approach to HIV prevention and care. Our results
also suggest that community-wide testing plus treatment programs can be both safe and
feasible. High testing rates are essential for any prevention strategy to be successful. Project
Accept thus sets a benchmark for evaluating the success of ongoing and future combination
Coates et al. Page 11
Lancet Glob Health. Author manuscript; available in PMC 2014 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
prevention trials that include a broader range of interventions, including increased provision
of treatment for HIV.
This was the first cluster-randomized trial with stigma reduction as a secondary endpoint.
However, stigma levels were low at baseline and had little room to decline further, possibly
due to social desirability bias. Similarly a recent trial investigating changes in stigma
through provision of home-based VCT in Zambia27 showed no effect and observed an
overall reduction in stigmatizing attitudes from baseline to follow-up. Further work is
needed to adequately measure the impact of stigma reduction efforts.
HIV incidence was estimated from a cross-sectional survey performed at the end of the
intervention period using a MAA developed and validated for this purpose. This was a novel
approach in HIV prevention research. It was not possible to measure incidence at baseline or
to use cohort follow-up to estimate incidence because either of those activities would have
interfered with the study intervention. Therefore, we could not adjust for baseline HIV
incidence or match the communities on HIV prevalence. Our validation studies suggest that
the MAA provided better precision than 6 months of cohort follow-up.22 The validation
studies also showed that the MAA had a negligible bias for estimating the intervention effect
and provided valid tests and confidence intervals. The incidence estimates we obtained were
consistent with those reported in cohort studies performed in regions with similar HIV
prevalence.28 Use of ART was addressed by excluding infections from the incidence
estimate if samples contained ARV drugs.14
Limitations
With the exception of the KwaZulu-Natal site, the observed HIV incidence and prevalence
at the African sites was lower than anticipated. Further, it was unfortunate that the Thailand
site had to be excluded due to very low prevalence. Much higher prevalence in Thailand was
anticipated, reflecting widespread injection drug use. In some communities, participation
rates were lower than desired, possibly influencing outcomes. It would also have been
helpful to have full information on the number of tests provided in both the CBVCT SVCT
communities, and to be able to track tests in CBVCT and SVCT communities. In South
Africa, there were no data on testing in the control communities and, at all sites, we could
not gather data on all testing that took place. We had no control over the variety of
approaches and alternative opportunities for HIV testing that might have been available, and
therefore we had no alternative but to use self-reported testing data to ensure comparability.
It should be noted, however, that the self-reports were collected from random probability
samples of the community members who may or may not have known that their community
was part of a study. The data were collected by assessors who had no knowledge of the
participant’s serostatus, thus reducing the potential for self-report bias.
Conclusions
Project Accept demonstrates what can happen when multi-component mobilization, testing,
and support services are implemented well. Even if treatment as prevention is proven
efficacious, the likelihood of implementing it well in most jurisdictions is low. We believe,
as well, that our results are sufficiently robust, especially taking the primary and secondary
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outcomes together, to recommend a combination of mobilization, mobile testing, post-test
support services, and monitoring and evaluation of service providers as routine components
of public health practice. The results of Project Accept demonstrate that modest reductions
in HIV incidence can be achieved using a multi-component, multi-level social and
behavioural intervention alone, in the absence of scale-up of other services and
implementation of structural and biomedical interventions. Project Accept also demonstrated
an effective method for increasing HIV testing and reducing HIV risk behaviour. High
testing rates are essential for any prevention strategy to be successful, and are an essential
first step in the implementation of any prevention strategy, especially treatment-as-
prevention. Project Accept thus sets a benchmark for evaluating the success of on-going and
future combination prevention trials that include a broader range of study interventions,
including increased provision of ART. It seems likely that the judicious combination and
application of behavioural, social, and biomedical interventions should achieve greater
reductions in HIV incidence in entire communities.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ART Antiretroviral Therapy
ARV Antiretroviral Drug
CI Confidence Interval
CBVCT Community-Based Voluntary Counseling and Testing
DSMB/SMC Data and Safety Monitoring Board and Study Monitoring Committee
HPTN HIV Prevention Trial Network
MAA Multi-Assay Algorithm
NIMH US National Institute of Mental Health
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PANEL: RESEARCH IN CONTEXT
Systematic review
An extraordinarily thorough systematic review and meta-analysis of community-based
voluntary HIV testing and counseling was published in August 2013 by Suthar et al.* For
this review, PubMed, clinical trial registries, Embase, and the World Health Organization
Global Index Medicus were searched for studies that included community-based HIV
testing and counseling (HTC). Both randomized controlled trials and observational
studies qualified if they included uptake, proportion receiving their first HIV test, CD4
value at diagnosis, linkage to care, HIV positivity rate, HTC coverage, HIV incidence,
and/or cost per person tested as outcomes. Eleven community-based HTC strategies were
reviewed. The reviewers then employed the Newcastle-Ottawa Quality Assessment Scale
and the Cochrane Collaboration's "risk of bias" tool to assess the risk of bias in studies
with a comparator arm included in pooled estimates. They found that 117 studies, which
included 864,651 participants completing HTC, met the inclusion criteria.
We also conducted separate searches on each secondary outcome we report in this paper.
We searched PubMed for relevant articles on experimental studies, and we placed no
restriction on date, or language. We searched the literature for experimental studies using
uptake of HIV testing as a primary or secondary outcome, using the following terms
(“HIV testing” OR “VCT”) AND (“utilization” OR “uptake”) AND (“trial” OR
“intervention”). Seventeen studies (11 randomized trials and six other experimental
designs), not including our own study, were found to assess the effect of an intervention
on uptake of HIV testing. For experimental studies aiming to effect social norms as
related to HIV testing we searched the following terms: (“HIV testing” OR “VCT”) AND
(“social norms” OR “community norms” OR “testing norms”) AND (“trial” OR
“intervention”). Our trial is the only experimental study we found in the literature, which
aimed to change social/community norms related to HIV testing. For experimental
studies aiming to affect HIV risk behavior through HIV testing and counseling we
searched the following terms: (“HIV testing” OR “VCT”) AND (“HIV risk” OR “risk
behaviors”) AND (“trial” OR “intervention”). Nine studies (7 randomized and 2 other
experimental designs), not including our own study, were found to assess the effect of
HIV testing and counseling on HIV risk behavior. For studies aiming to affect HIV
related discussions as related to HIV testing and counseling we searched the following
terms (“HIV testing” OR “VCT”) AND (“HIV discussions” OR “HIV communication”)
AND (“trial” OR “intervention”). One randomized trial was found to have assessed the
effect of HIV testing and counseling on HIV related discussions. For studies aiming to
affect HIV stigma as related to HIV testing and counseling we searched the following
terms: (“HIV testing” OR “VCT”) AND (“HIV stigma” OR “stigma”) AND (“trial” OR
“intervention”). One randomized trial and one experimental study (non-randomized) was
found to have assessed the effect of an intervention on HIV stigma as related to HIV
testing and counseling.
Interpretation
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The reviewers found that mobile HTC uptake among key populations (men who have sex
with men, people who inject drugs, female sex workers, and adolescents) ranged from
9% to 100% (among 41,110 participants across studies), with heterogeneity related to
how HIV testing was offered. They found that community-based approaches increased
HTC uptake (relative risk [RR] 10.65, 95% confidence interval [CI] 6.27–18.08), the
proportion of first-time testers (RR 1.23, 95% CI 1.06–1.42), and the proportion of
participants with CD4 counts above 350 cells/µl (RR 1.42, 95% CI 1.16–1.74), and
obtained a lower positivity rate (RR 0.59, 95% CI 0.37–0.96), relative to facility-based
approaches. They found that 80% (95% CI 75%-85%) of 5,832 community-based HTC
participants obtained a CD4+ T-cell measurement following diagnosis of HIV, and 73%
(95% CI 61%-85%) of 527 community-based HTC participants started antiretroviral
therapy following a CD4+ T-cell measurement signifying eligibility. Data on linking
HIV-negative participants to prevention services were limited. No studies reported harm
as a result of having been tested. In these studies, community-based HTC achieved high
rates of HTC uptake, reached people with high CD4+ T-cell counts, and linked people to
care. It also obtained a lower HIV positivity rate relative to facility-based approaches.
Numerous studies, including Project Accept, have documented substantial benefit when
using community-based HCT. None have demonstrated an effect in lowering HIV
incidence and few have documented the effects on special populations at risk (eg, men),
on HIV risk behavior, and on community social norms regarding HIV. While numerous
studies have tested the effectiveness of single interventions on the uptake of HIV testing,
few experimental studies have tested the effect of combining social, behavioral and
structural interventions to address barriers to HIV testing or change in community norms
that lead to decreased HIV transmission.
*
 Suthar AB, Ford N, Bachanas PJ, et al. Towards Universal Voluntary HIV Testing and
Counselling: A Systematic Review and Meta-Analysis of Community-Based
Approaches. PLOS Medicine. 2013 Aug; 10(8): e1001496.
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Figure 1.
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Figure 2.
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Figure 3.
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Figure 4.
Participant Flow Diagram
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